This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Wright Medical Group, Inc. Reports 2012 Second Quarter Financial Results

Stocks in this article: WMGI

About Wright Medical

Wright Medical Group, Inc. is a global orthopaedic medical device company and a leading provider of surgical solutions for the foot and ankle market. The Company specializes in the design, manufacture and marketing of devices and biologic products for extremity, hip and knee repair and reconstruction. The Company has been in business for more than 60 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit the Company's website at www.wmt.com.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as net sales, excluding the impact of foreign currency; operating income, as adjusted; net income, as adjusted; net income, as adjusted, per diluted share; effective tax rate, as adjusted; and free cash flow. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. The measures exclude such items as costs related to the U.S. governmental inquiries and the DPA, costs associated with distributor conversions and non-competes, restructuring charges, transaction costs, charges associated with the Company's liability for PROFEMUR ® long modular neck claims, costs related to settlement of certain employment matters and the hiring of a new CEO, and non-cash stock-based expense, all of which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” as defined under U.S. federal securities laws, including statements regarding potential actions by the USAO, independent monitor, OIG and other agencies or their potential impact. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. The reader should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date. Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2011 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, under the heading “Risk Factors” and elsewhere); future actions of the FDA or any other regulatory body or government authority that could delay, limit or suspend product development, manufacturing or sale or result in seizures, injunctions, monetary sanctions or criminal or civil liabilities; the impact of any such future actions of the FDA or any other regulatory body or government authority on our settlement of the federal investigation into our consulting arrangements with orthopaedic surgeons relating to our hip and knee products in the United States; the impact of such settlement of the federal investigation into our consulting arrangements with orthopaedic surgeons relating to our hip and knee products in the United States, including our compliance with the Deferred Prosecution Agreement through September 2012 and the Corporate Integrity Agreement through September 2015; and compliance reviews, the results of which may be required to be disclosed to government authorities, and which may uncover violations of law, including strict liability provisions of the federal Food, Drug and Cosmetic Act, that could lead to adverse action by the FDA or others. Our failure to comply with the Deferred Prosecution Agreement or the Corporate Integrity Agreement could expose us to significant liability including, but not limited to, exclusion from federal healthcare program participation, including Medicaid and Medicare, which would have a material adverse effect on our financial condition, results of operations and cash flows, potential prosecution, including under the previously-filed criminal complaint, civil and criminal fines or penalties, and additional litigation cost and expense. In addition, a breach of the DPA or the CIA could result in an event of default under the Senior Credit Facility, which in turn could result in an event of default under the Indenture.

Additional risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include the possibility of litigation brought by shareholders, including private securities litigation and shareholder derivative suits, which if initiated, could divert management's attention, harm our business and/or reputation and result in significant liabilities; demand for and market acceptance of our new and existing products; future actions of governmental authorities and other third parties; tax measures; business development and growth opportunities; product quality or patient safety issues; products liability claims; enforcement of our intellectual property rights; the geographic and product mix impact on our sales; retention of sales representatives and independent distributors; inventory reductions or fluctuations in buying patterns by wholesalers or distributors; ability to realize the anticipated benefits of restructuring initiatives; impact of the commercial and credit environment on us and our customers and suppliers; and in the implementation of our new compliance enhancements, including the duration and severity of delays related to medical education, research and development and clinical studies, and the impact of any such delays on our relationships with customers.

       

Wright Medical Group, Inc. Condensed Consolidated Statements of Operations(in thousands, except per share data--unaudited)

 
Three Months Ended Six Months Ended
June 30, 2012     June 30, 2011 June 30, 2012     June 30, 2011
Net sales $ 123,280 $ 132,505 $ 249,936 $ 267,891
Cost of sales 38,434 41,504 75,240 80,272
Cost of Sales - restructuring     435  
Gross profit 84,846 91,001 174,261 187,619
Operating expenses:
Selling, general and administrative 72,862 70,821 145,210 145,646
Research and development 6,744 7,807 12,965 17,014
Amortization of intangible assets 1,254 677 1,996 1,367
Restructuring charges 710     1,153  
Total operating expenses 81,570   79,305   161,324   164,027
Operating income 3,276 11,696 12,937 23,592
Interest expense, net 1,887 1,475 3,694 3,310
Other (income) expense, net (153 ) 257   8   4,716
Income before income taxes 1,542 9,964 9,235 15,566
Provision for income taxes 832   3,817   3,964   5,827
Net income $ 710   $ 6,147   $ 5,271   $ 9,739
Net income per share, basic $ 0.02   $ 0.16   $ 0.14   $ 0.26
Net income per share, diluted $ 0.02   $ 0.16   $ 0.14   $ 0.25
Weighted-average number of shares outstanding-basic 38,715   38,240   38,604   38,137
Weighted-average number of shares outstanding-diluted 38,997   39,261   38,898   38,347
       

Wright Medical Group, Inc. Consolidated Sales Analysis(dollars in thousands--unaudited)

 
Three Months Ended Six Months Ended
June 30, 2012     June 30, 2011     %

change

June 30, 2012     June 30, 2011     %

change

Geographic

Domestic $ 69,216 $ 75,354 (8.1 %) $ 139,278 $ 153,296 (9.1 %)
International 54,064   57,151   (5.4 %) 110,658     114,595     (3.4 %)
Total net sales $ 123,280   $ 132,505   (7.0 %) $ 249,936     $ 267,891     (6.7 %)
 
Three Months Ended Six Months Ended
June 30, 2012 June 30, 2011 %

change

June 30, 2012   June 30, 2011   %

change

OrthoRecon

Hips $ 40,073 $ 45,544 (12.0 %) $ 81,573 $ 91,441 (10.8 %)
Knees 30,189 33,392 (9.6 %) 61,271 66,225 (7.5 %)
Other 1,054   1,329   (20.7 %) 2,255     2,618     (13.9 %)
Total OrthoRecon 71,316 80,265 (11.1 %) 145,099 160,284 (9.5 %)
 

Extremities

Foot and Ankle 28,880 25,804 11.9 % 58,507 52,529 11.4 %
Upper Extremity 6,349 6,949 (8.6 %) 12,894 14,497 (11.1 %)
Biologics 15,454 17,929 (13.8 %) 30,641 37,236 (17.7 %)
Other 1,281   1,558   (17.8 %) 2,795     3,345     (16.4 %)
Total Extremities 51,964 52,240 (0.5 %) 104,837 107,607 (2.6 %)
               
Total Sales $ 123,280   $ 132,505   (7.0 %) $ 249,936     $ 267,891     (6.7 %)
   

Wright Medical Group, Inc. Supplemental Sales Information(unaudited)

 
Second Quarter 2012 Sales Growth
Domestic

As

Reported

    Int'l

Constant

Currency

    Int'l

As

Reported

    Total

Constant

Currency

    Total

As

Reported

OrthoRecon

Hips (19%) (4%) (8%) (10%) (12%)
Knees (15%) 0% (3%) (8%) (10%)
Other (13%) (19%) (22%) (18%) (21%)
Total OrthoRecon (17%) (3%) (7%) (9%) (11%)
 

Extremities

Foot and Ankle 11% 23% 14% 13% 12%
Upper Extremity (10%) (1%) (4%) (8%) (9%)
Biologics (16%) 0% (3%) (13%) (14%)
Other 25% (27%) (32%) (14%) (18%)
Total Extremities (1%) 7% 1% 1% (1%)
         
Total Sales (8%) (1%) (5%) (5%) (7%)
    Sales as a % of Total Sales
Three Months Ended June 30, 2012     Six Months Ended June 30, 2012
Domestic     International     Total Domestic     International     Total

OrthoRecon

Hips 11% 22% 33% 10% 22% 33%
Knees 12% 12% 24% 12% 12% 25%
Other 0% 1% 1% 0% 1% 1%
Total OrthoRecon 23% 35% 58% 23% 35% 58%
 

Extremities

Foot and Ankle 19% 4% 23% 19% 4% 23%
Upper Extremity 4% 2% 5% 4% 2% 5%
Biologics 10% 3% 13% 10% 2% 12%
Other 0% 1% 1% 0% 1% 1%
Total Extremities 33% 9% 42% 33% 9% 42%
           
Total Sales 56% 44% 100% 56% 44% 100%
       

Wright Medical Group, Inc. Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency(dollars in thousands--unaudited)

 
Three Months Ended Six Months Ended
June 30, 2012 June 30, 2012

International Net Sales

   

Total Net Sales

International Net Sales

   

Total Net Sales

Net sales, as reported $ 54,064 $ 123,280 $ 110,658 $ 249,936
Currency impact as compared to prior period 2,406 2,406 2,574   2,574
Net sales, excluding the impact

of foreign currency

$ 56,470 $ 125,686 $ 113,232 $ 252,510
       

Wright Medical Group, Inc. Reconciliation of As Reported Results to Non-GAAP Financial Measures(in thousands, except per share data--unaudited)

 
Three Months Ended   Six Months Ended
June 30, 2012     June 30, 2011   June 30, 2012     June 30, 2011
Operating Income
Operating income, as reported $ 3,276 $ 11,696 $ 12,937 $ 23,592
Reconciling items impacting Gross Profit:
Non-cash, stock-based compensation 348 360 694 707
Cost of sales - restructuring 435
Inventory step-up amortization 48     96    
Total 396   360   1,225   707  
Reconciling items impacting Selling, General and Administrative expenses:
Non-cash, stock-based compensation 2,805 1,300 4,691 3,368
DPA related 2,072 2,385 4,940 4,567
Distributor conversions 208       208      
Total 5,085   3,685     9,839     7,935  
Reconciling items impacting Research and Development expenses:
Non-cash, stock-based compensation 236 (53 ) 387 392
Reconciling items impacting Amortization of Intangible Assets:
Amortization of distributor non-competes 571 571
Other Reconciling Items:
Restructuring charges 710       1,153      
Operating income, as adjusted $ 10,274   $ 15,688     $ 26,112     $ 32,626  
Operating income, as adjusted, as a

percentage of net sales

8.3 % 11.8 %   10.4 %   12.2 %
       

Wright Medical Group, Inc. Reconciliation of As Reported Results to Non-GAAP Financial Measures(in thousands, except per share data--unaudited)

 
Three Months Ended   Six Months Ended
June 30, 2012     June 30, 2011   June 30, 2012     June 30, 2011
Net Income
Income before taxes, as reported $ 1,542 $ 9,964 $ 9,235 $ 15,566
Pre-tax impact of reconciling items:
Non-cash, stock-based compensation 3,389 1,607 5,772 4,467
DPA related 2,072 2,385 4,940 4,567
Restructuring charges 710 1,588
Inventory step-up amortization 48 96
Distributor conversion and non-competes 779 779
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer           4,099  
Income before taxes, as adjusted 8,540 13,956 22,410 28,699
 
Provision for income taxes, as reported 832 3,817 3,964 5,827
Non-cash, stock-based compensation 1,090 219 1,384 1,066
DPA related 681 930 2,149 1,782
Restructuring charges 276 620
Inventory step-up amortization 18 37
Distributor conversion and non-competes 339 339
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer           1,599  
Provision for income taxes, as adjusted $ 3,236   $ 4,966     $ 8,493     $ 10,274  
Effective tax rate, as adjusted 37.9 % 35.6 %   37.9 %   35.8 %
Net income, as adjusted $ 5,304   $ 8,990     $ 13,917     $ 18,425  
       

Wright Medical Group, Inc. Reconciliation of As Reported Results to Non-GAAP Financial Measures (continued)

 
Three Months Ended Three Months Ended
June 30, 2012 June 30, 2011
As Reported     As Adjusted As Reported     As Adjusted
Basic net income $ 710 $ 5,304 $ 6,147 $ 8,990
Interest expense on convertible notes   N/A   N/A   137     137  
Diluted net income $ 710 $ 5,304 $ 6,284 $ 9,127
 
Basic shares 38,715 38,715 38,240 38,240
Dilutive effect of stock options and restricted shares 282 282 130 130
Dilutive effect of convertible notes   N/A   N/A   891     891  
Diluted shares 38,997 38,997 39,261 39,261
 
Net income per share, diluted $ 0.02 $ 0.14 $ 0.16   $ 0.23  
 
Six Months Ended Six Months Ended
June 30, 2012 June 30, 2011
As Reported As Adjusted As Reported As Adjusted
Basic net income $ 5,271 $ 13,917 $ 9,739 $ 18,425
Interest expense on convertible notes   N/A   275   N/A     929  
Diluted net income $ 5,271 $ 14,192 $ 9,739 $ 19,354
 
Basic shares 38,604 38,604 38,137 38,137
Dilutive effect of stock options and restricted shares 294 294 210 210
Dilutive effect of convertible notes   N/A   891   N/A     2,927  
Diluted shares 38,898 39,789 38,347 41,274
 
Net income per share, diluted $ 0.14 $ 0.36 $ 0.25   $ 0.47  
 
Three Months Ended Six Months Ended
June 30, 2012 June 30, 2011   June 30, 2012 June 30, 2011
Net Income per Diluted Share

Net income, as reported, per diluted share

$ 0.02 $ 0.16 $ 0.14 $ 0.25
Interest expense on convertible notes N/A N/A 0.01 0.02
Effect of convertible notes on diluted shares N/A N/A (0.01 ) (0.02 )
Non-cash, stock-based compensation 0.06 0.04 0.11 0.08
DPA related 0.04 0.04 0.08 0.07
Restructuring charges 0.01 0.02
Inventory step-up amortization 0.00 0.00 0.00
Distributor conversion and non-competes 0.01 0.01
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer   N/A       N/A     0.06  

Net income, as adjusted, per diluted share

$ 0.14 $ 0.23   $ 0.36   $ 0.47  
       

Wright Medical Group, Inc. Reconciliation of Free Cash Flow(dollars in thousands--unaudited)

 
Three Months Ended Six Months Ended
June 30, 2012     June 30, 2011   June 30, 2012     June 30, 2011
Net cash provided by operating activities 22,033 20,868 41,113 39,016
Capital expenditures (4,042 ) (13,291 )   (8,573 ) (23,376 )
Free cash flow 17,991   7,577     32,540   15,640  
   

WRIGHT MEDICAL GROUP, INC. Segment Income Statement (In thousands, except share data) (unaudited)

 
Three Months Ended June 30, 2012
OrthoRecon     Extremities     Corporate     Other (1)     Total
Net sales $ 71,316 $ 51,964 $ $ $ 123,280
Cost of sales 26,485   11,553     396   38,434  
Gross profit 44,831 40,411 (396 ) 84,846
 
Operating expenses:
Selling, general and administrative 30,720 24,336 12,721 5,085 72,862
Research and development 3,141 3,367 236 6,744
Amortization of intangible assets 83 600 571 1,254
Restructuring charges       710   710  
Total operating expenses 33,944 28,303 12,721 6,602 81,570
         
Operating income $ 10,887   $ 12,108   $ (12,721 ) $ (6,998 ) $ 3,276  
 
Operating income as a percent of net sales 15.3 % 23.3 % N/A N/A 2.7 %
 
Three Months Ended June 30, 2012
OrthoRecon Extremities Corporate Other Total
Depreciation expense $ 6,175 $ 2,789 $ 588 $ $ 9,552
Amortization expense 83 600 571 1,254
Capital expenditures 680 2,277 1,085 4,042

______________________________

(1) Other consists exclusively of the reconciling items from Operating Income, as reported, to Operating Income, as adjusted, as included in the reconciliations above.

   

WRIGHT MEDICAL GROUP, INC. Segment Income Statement (continued)

 
Three Months Ended June 30, 2011
OrthoRecon     Extremities     Corporate     Other (1)     Total
Net sales $ 80,267 $ 52,238 $ $ $ 132,505
Cost of sales 25,865   15,279     360   41,504  
Gross profit 54,402 36,959 (360 ) 91,001
 
Operating expenses:
Selling, general and administrative 32,125 21,499 13,512 3,685 70,821
Research and development 4,552 3,308 (53 ) 7,807
Amortization of intangible assets 106   571       677  
Total operating expenses 36,783 25,378 13,512 3,632 79,305
         
Operating income $ 17,619   $ 11,581   $ (13,512 ) $ (3,992 ) $ 11,696  
 
Operating income as a percent of net sales 22.0 % 22.2 % N/A N/A 8.8 %
 
Three Months Ended June 30, 2011
OrthoRecon Extremities Corporate Other Total
Depreciation expense $ 6,629 $ 2,640 $ 527 $ $ 9,796
Amortization expense 106 571 677
Capital expenditures 6,197 2,535 4,559 13,291

____________________________

(1) Other consists exclusively of the reconciling items from Operating Income, as reported, to Operating Income, as adjusted, as included in the reconciliations above.

   

WRIGHT MEDICAL GROUP, INC.Segment Income Statement(continued)

 
Six Months Ended June 30, 2012
OrthoRecon     Extremities     Corporate     Other (1)     Total
Net sales $ 145,099 $ 104,837 $ $ $ 249,936
Cost of sales 51,688   22,762     1,225   75,675
Gross profit 93,411 82,075 (1,225 ) 174,261
 
Operating expenses:
Selling, general and administrative 62,060 48,422 24,889 9,839 145,210
Research and development 5,927 6,651 387 12,965
Amortization of intangible assets 217 1,208 571 1,996
Restructuring charges       1,153   1,153
Total operating expenses 68,204 56,281 24,889 11,950 161,324
         
Operating income $ 25,207   $ 25,794   $ (24,889 ) $ (13,175 ) $ 12,937
 
Operating income as a percent of net sales 17.4% 24.6% N/A N/A 5.2%
 
Six Months Ended June 30, 2012
OrthoRecon Extremities Corporate Other Total
Depreciation expense $ 12,572 $ 5,653 $ 1,671 $ $ 19,896
Amortization expense 217 1,208 571 1,996
Capital expenditures 2,574 4,450 1,549 8,573

______________________________

(1) Other consists exclusively of the reconciling items from Operating Income, as reported, to Operating Income, as adjusted, as included in the reconciliations above.

   

WRIGHT MEDICAL GROUP, INC. Segment Income Statement (continued)

 
Six Months Ended June 30, 2011
OrthoRecon     Extremities   Corporate     Other (1)     Total
Net sales $ 160,284 $ 107,607 $ $ $ 267,891
Cost of sales 51,510   28,055     707   80,272  
Gross profit 108,774 79,552 (707 ) 187,619
 
Operating expenses:
Selling, general and administrative 65,570 45,968 26,173 7,935 145,646
Research and development 9,200 7,422 392 17,014
Amortization of intangible assets 192   1,175       1,367  
Total operating expenses 74,962 54,565 26,173 8,327 164,027
         
Operating income $ 33,812   $ 24,987   $ (26,173 ) $ (9,034 ) $ 23,592  
 
Operating income as a percent of net sales 21.1 % 23.2 % N/A N/A 8.8 %
 
Six Months Ended June 30, 2011
OrthoRecon Extremities Corporate Other Total
Depreciation expense $ 13,002 $ 5,170 $ 1,066 $ $ 19,238
Amortization expense 192 1,175 1,367
Capital expenditures 11,286 5,136 6,954 23,376

______________________________

(1) Other consists exclusively of the reconciling items from Operating Income, as reported, to Operating Income, as adjusted, as included in the reconciliations above.

       

WRIGHT MEDICAL GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) (unaudited)

 
June 30, 2012

December 31, 2011

Assets:
Current assets:
Cash and cash equivalents $ 176,591 $ 153,642
Marketable securities 16,297 13,597
Accounts receivable, net 102,591 98,995
Inventories 157,123 164,600
Prepaid expenses and other current assets 58,641 69,699
Total current assets 511,243 500,533
 
Property, plant and equipment, net 147,032 160,284
Goodwill and intangible assets, net 79,247 75,651
Marketable securities 4,502
Other assets 14,471 13,610
Total assets $ 751,993 $ 754,580
 
Liabilities and Stockholders’ Equity:
Current liabilities:
Accounts payable $ 9,385 $ 11,651
Accrued expenses and other current liabilities 57,514 55,831
Current portion of long-term obligations 10,346 8,508
Total current liabilities 77,245 75,990
Long-term obligations 150,679 166,792
Other liabilities 45,539 43,334
Total liabilities $ 273,463 $ 286,116
   
Stockholders’ equity: 478,530 468,464
Total liabilities and stockholders’ equity $ 751,993 $ 754,580




5 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASDAQ 4,382.8470 -36.6310 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs